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Editorial Summary: This protocol describes how to grow a functional and transplantable corneal 1 
epithelium and how to generate ocular-like cell lineages resembling neuroectoderm, neural 2 
crest, ocular surface ectoderm or surface ectoderm derived from human iPS cells. 3 
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ABSTRACT 1 
We describe a protocol for the generation of a functional and transplantable corneal epithelium 2 
derived from human induced pluripotent stem (iPS) cells. In our experiments a proportion of 3 
iPS cells spontaneously form circular colonies, each of which is comprised of four concentric 4 
zones. Cells in these zones have different morphologies and immunostaining characteristics, 5 
resembling neuroectoderm, neural crest, ocular surface ectoderm or surface ectoderm. We term 6 
this two-dimensional (2D) colony a SEAM (a self-formed, ectodermal, autonomous, multi-7 
zone), and propose that cells within it have the potential to give rise to anlages of different 8 
ocular lineages including retinal cells, lens cells, and ocular surface ectoderm. To investigate the 9 
translational potential of the SEAM, cells within it that resembled ocular surface epithelia were 10 
isolated by pipetting and sorted by FACS into a population of corneal epithelial-like progenitor 11 
cells. These were then expanded and differentiated to form an epithelial layer, which expressed 12 
K12 and PAX6 and which was able to recover function in an animal model of corneal epithelial 13 
dysfunction after surgical transplantation. The whole protocol, encompassing human iPS cell 14 
preparation, autonomous differentiation, purification and subsequent differentiation takes 15 
between 100 and 120 days, and is of potential use to researchers with an interest in eye 16 
development and/or ocular surface regeneration. We suggest that experience with human iPS 17 
cell culture and sorting via FACS will be of benefit for researchers performing this protocol. 18 
19 
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INTRODUCTION 1 
Induced pluripotent stem (iPS) cells are highly influential in life sciences research, and the 2 
fields of fundamental and translational eye research are no exceptions1,2. Noteworthy in this 3 
regard are studies that have used embryonic stem (ES) cells and iPS cells to advance our 4 
knowledge of ocular morphogenesis, and the potential of stem cell-derived tissue for surgical 5 
use3-7. The front of the eye is formed by the cornea, a curved and clear collagen-rich tissue that 6 
is overlaid by a specialised multi-layered epithelium that supports the tear-film. Research into 7 
the corneal epithelium is active owing to the prevalence of blinding and difficult-to-treat ocular 8 
surface injuries or diseases. At present, convincing methods for the production of corneal 9 
epithelial stem cells and progenitor cells by direct differentiation from iPS cells, and the 10 
subsequent expansion of these cells into functional epithelial tissues, are lacking. To try to 11 
address this and to investigate the possible generation of multiple ocular cell lineages, we 12 
recently reported the fabrication of a self-formed, ectodermal, autonomous, multi-zone (SEAM) 13 
of ocular cells from human iPS cells8. The SEAM contains four concentric zones of cells, each 14 
of which has the characteristics of a particular ocular cell lineage or lineages. From the cell zone 15 
of the SEAM that most closely resembles the ocular surface epithelium we isolated and sorted 16 
functional corneal epithelial stem/progenitor cells8. Here, we report a detailed protocol for 17 
generating a SEAM from human iPS cells and the subsequent fabrication of functional corneal 18 
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epithelial cell sheets. 1 
 2 
Development of the Protocol  3 
Recent research with pluripotent stem cells in culture has identified a previously 4 
underappreciated level of intrinsic cellular self-organization, and has provided evidence of 5 
cupping of the neural retina when a three-dimensional (3D) culture system was used4. However, 6 
this work provided no signs of ocular surface development. We have now developed a culture 7 
technique that can partially mimic whole eye development encompassing all key ocular 8 
component tissues. To achieve this, we adopt a 2D culture system and use laminin 511 E8-9 
fragment as a substrate for ocular cell growth. Various types of serum-free differentiation 10 
medium were used to promote spontaneous eye-like differentiation of human iPS cells. 11 
 12 
Comparison with other methods 13 
As mentioned, research using 3D culture techniques has successfully demonstrated spontaneous 14 
retinal tissue formation from human iPS cells4. However, this approach has not led to the 15 
generation of corneal or other anterior eye tissues. It has also been shown, by us and others, that 16 
the use of a 2D-culture system with feeder cells or their conditioned medium (e.g. corneal 17 
limbal fibroblasts or PA6 mouse feeder cells) is able to induce corneal epithelial-like cells from 18 
iPS cells, but the purification of these cells was ultimately not achievable9,10. In essence, these 19 
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cells appeared to be “corneal epithelial-like cells” and, indeed, they expressed corneal epithelial 1 
markers. But, ultimately, they did not undergo subsequent physiological development and 2 
differentiation9-11. The protocol we describe here is distinct because it generates a range of 3 
cellular anlages that have characteristics of several quite separate tissues in the eye. The culture 4 
techniques do not require the use of feeder cells or FBS, and the iPS cell-derived corneal 5 
epithelial stem and progenitor cells undergo purification by FACS using a combination of 6 
antibodies. This approach confers a crucial advantage for future potential clinical applications 7 
because the final product (i.e. the corneal epithelial cell sheets) will be devoid of non-corneal 8 
iPS-derived epithelial cells and of cellular impurities that might originate from feeder cells. 9 
 10 
Limitations 11 
In this series of experiments, it became apparent that different human iPS cell clones had 12 
different propensities for differentiation. Indeed, some clones only infrequently formed a SEAM 13 
or resulted in the successful generation of a FACS-sorted corneal epithelial cell layer. 14 
Commercially available 201B7 and 454E2 iPS cell clones, along with clone 1383D2, provided 15 
by the Center for iPS Cell Research and Applications (CiRA) at Kyoto University, displayed a 16 
good differentiation potential. Clone 253G1, on the other hand, was found to be poor in terms of 17 
its differentiation into corneal epithelium8. This differential differentiation propensity of 18 
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different human iPS cell clones might be a consequence of dissimilarities in epigenetic status11-1 
13
, but at this stage of our research it is too early to definitively identify a particular human iPS 2 
cell clone(s) as best-suited for use in SEAM-formation and subsequent corneal differentiation. 3 
Of course, this question could be resolved by optimizing the cultivation protocol for each 4 
human iPS cell clone, but we have not undertaken this task. As such, and based on our 5 
experience to date, it would seem sensible to recommend the use of clone 201B7, a frequently 6 
used clone in the field of human iPS cell research14-16, for the experiments we describe. Finally, 7 
we note that the protocol described here, especially in its latter parts, is targeted at inducing 8 
corneal epithelial cells from the human iPS cell-derived SEAM. Effectively obtaining other cell 9 
types such as neural crest cells or presumptive lens cells will likely require modifications to the 10 
protocol. 11 
 12 
Applications 13 
SEAMs generated by this protocol have potential use as in vitro cellular models for human eye 14 
development. This will likely be of significant interest for research into human eye 15 
development, particularly in the early stages, because most current information is based on 16 
mouse or avian eye development. Moreover, because human iPS cells can be infinitely 17 
amplified in culture a SEAM has the potential to act as a significant research resource for 18 
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human ocular cells, such as retinal cells or corneal epithelial cells, which are difficult to obtain 1 
otherwise. 2 
 3 
Experimental Design 4 
This protocol is described in two parts: the first covers the human iPS cell culture and SEAM 5 
formation (Steps 1–34; PART I); the second, the isolation of corneal epithelial cells from the 6 
SEAM and their fabrication into functional and transplantable cell sheets (Steps 35–59; PART 7 
II) (Fig.1). 8 
 9 
PART I: Human iPS cell culture and SEAM formation (Steps 1–34) Human iPS cells to be 10 
used for SEAM-formation and subsequent corneal epithelial differentiation were maintained on 11 
Laminin-511 E8 fragment (LN511E8)-coated culture dishes in serum-free medium (StemFitTM 12 
medium) for a minimum of three to four cell passages before initiating differentiation15,17 (Fig. 13 
2). The initial seeding density -- typically, we use 1500-4500 cells/6-well plate -- is an important 14 
factor for the differentiation propensity. For example, at higher cell densities (e.g. 4500-6000 15 
cells/6-well plate) the likelihood of corneal epithelial differentiation is enhanced. Seeding at 16 
lower cell densities, (e.g. 1000-2000 cells/6-well plate), on the other hand, has the effect of 17 
encouraging neural crest differentiation. 18 
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 1 
After the initial cell passaging, cultivation was continued in specific growth factor-free medium 2 
(Differentiation medium; DM), whilst still on LN511E8, until the formation of a SEAM (Fig. 3 
3A). As we reported recently8, a typical SEAM contains neuronal cells in the innermost zone 4 
(zone 1), retina-like and neural crest-like cells in the adjacent radial zone (zone 2), ocular 5 
surface ectoderm-like cells in the next zone outwardly (zone 3), lens-like cells in zones 2 and 3, 6 
and non-ocular surface epithelial-like cells in the outermost zone (zone 4) (Fig. 3B). 7 
After approximately four weeks of differentiation culture, we examined each zonal cell 8 
population in the SEAM via immunofluorescence staining (Box 1). To verify the existence of 9 
ocular cell lineages in each zone, the following antibody combinations were used and are 10 
recommended: a PAX6/p63-double-positive phenotype for ocular surface ectoderm (an anlage 11 
of the corneal epithelium)8,18,19; TUBB3 and p63 for neuronal/epithelial cells20-22; CHX10 and 12 
MITF for neural-retina/retinal pigment epithelium (RPE)8,23; SOX10 and p75 for neural crest 13 
cells8,24; and PAX6/-crystallin for lens cells25,26 (Fig. 3B, Table 1). 14 
 15 
At the four-week timepoint we further studied cells in zone 3, i.e. those with characteristics of 16 
the ocular surface ectoderm, anlages of corneal epithelial stem and progenitor cells. To do this 17 
the SEAM was further cultivated in corneal differentiation medium (CDM) containing growth 18 
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factors and the ROCK inhibitor, Y-27632, for an additional four weeks. Three weeks into this 1 
CDM culture period, (i.e. after seven weeks total culture time) we remove zone 1 and 2 cells 2 
from the SEAM by manual pipetting, as is described later. During this second culture period, 3 
immature ocular surface ectodermal cells proliferate and gradually differentiate into what will 4 
later become functional corneal epithelial stem/progenitor cells. (As an alternative option for 5 
encouraging retinal cell differentiation, we suggest a direct switch to corneal epithelial medium 6 
(CEM), rather than CDM after the initial four week differentiation in DM).   7 
 8 
PART II: Isolation of corneal epithelial cells from the SEAM and their fabrication into 9 
functional and transplantable cell sheets (Steps 35–59). As mentioned, corneal epithelial-like 10 
stem/progenitor cells form zone 3 of the SEAM. Immunolabelling shows that cells with 11 
characteristics of other ocular cell lineages (i.e. retinal cells, lens cells, or neuronal cells) are 12 
generated in other zones of the same SEAM in the same culture dish (Fig. 1, 3B). To enrich and 13 
purify corneal epithelial-like cells, we remove these non-epithelial cellular zones from the 14 
SEAM by manual pipetting (Fig. 4A). This can be carried out at around seven weeks of 15 
differentiation, i.e. three weeks into the four-week CDM culture period. As described later, the 16 
pipetting can selectively remove neuronal-like cells from zones 1 and 2 of the SEAM without 17 
removing the cells in zones 3 and 4 because these adhere more tightly to the culture dish. After 18 
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pipetting away zone 1-2 cells, those remaining are further differentiated for an additional week 1 
in CDM, so that a total of four weeks in CDM is achieved. Following this, i.e. at the eight-week 2 
timepoint, the culture medium is switched to CEM (Fig. 4B) and cultivation is continued for a 3 
further four weeks. Thus, the recommended culture time is 12 weeks in total, although this can 4 
be reduced to 10-weeks by performing an abridged two-week CEM cultivation. This, however, 5 
carries the risk of lessening the efficiency of corneal differentiation, which becomes more stable 6 
after 12 weeks. (The maximum recommended culture time, depending on the logistics of the 7 
experiments, is 16 weeks, which can be achieved by extending the final CEM cultivation period 8 
to eight weeks). At the recommended 12-week timepoint FACS was performed using anti-9 
ITGB4, SSEA-4, and TRA-1-60 antibodies to isolate corneal epithelial stem/progenitor cells 10 
(Fig. 4C). TRA-1-60, a pluripotent stem cell marker, was used to remove undifferentiated iPS 11 
cells14,27, ITGB4 was used to select basal cells of the stratified epithelium, rich in epithelial 12 
stem/progenitor cells8,28,29, whilst SSEA-4 was employed as it is expressed in corneal epithelial 13 
cells as well as in a significant proportion of stem and progenitor cells in the corneal epithelial 14 
stem cell niche at the edge of the cornea at the limbus of the eye8,30. This approach enabled the 15 
high-purity isolation of corneal epithelial stem/progenitor cells consisting of TRA-1-60-16 
/ITGB4+/SSEA-4+ cells. 17 
 18 
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After sorting in this way, the FACS-isolated corneal stem/epithelial progenitor cells were 1 
allowed to proliferate and form epithelial colonies on LN511E8-coated dishes in a feeder-less 2 
culture system. After reaching confluence, cells became stratified and had formed a multi-3 
layered structure. To conduct cell-sheet transplantation in an animal model of corneal epithelial 4 
injury, we harvested cell sheets at this juncture (i.e. after two-to-three weeks in culture). Sheets 5 
were recoverable as intact cellular constructs, similar to those we have used in previous corneal 6 
epithelial transplantation investigations31. Additionally, longer-term cultivation (up to 10 weeks) 7 
of the sorted cells was conducted to promote cellular stratification and maturation, after which 8 
we performed immunofluorescence microscopy to examine how patterns of protein expression 9 
compared to those of normal cultivated human corneal limbal epithelium (Box 2). We 10 
recommend immunofluorescence staining using the corneal epithelial-specific markers, K3, 11 
K12, PAX6, p63, MUC1 and MUC16 (Fig. 5). 12 
 13 
MATERIALS 14 
Human iPS cell (201B7; RIKEN Bio Resource Center, #HPS0063) 15 
Caution: All work with human iPS cells must be carried out in accordance with all relevant 16 
institutional and governmental regulations, applicable in the investigator’s home laboratory and 17 
country. In our case, the experiments were approved by the Recombinant DNA Committees of 18 
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Osaka University and were performed according to our institutional guidelines. 1 
Critical: Human iPS cells should be routinely verified by microscopic observation. They should 2 
exist as circular colonies composed of uniformly packed cells that exhibit immunostaining for 3 
pluripotent stem cell markers, TRA-1-60 and SSEA-4. 4 
Caution: The 201B7 human iPS cell line was tested as Mycoplasma negative by the provider 5 
and by us. Human iPS cells should be regularly tested for Mycoplasma contamination by an 6 
appropriate method (e.g., we used a PCR-based method employing the e-MycoTM Mycoplasma 7 
PCR Detection Kit; iNtRON Biotechnology, # 25235). 8 
PE-conjugated CD104 (ITGB4) (58BX4; Bio Legend, #327808) 9 
PE-conjugated isotype control IgG (MOPC-173; BioLegend, #400214) 10 
FITC-conjugated SSEA-4 (MC-813-70; BioLegend, #330410) 11 
FITC-conjugated isotype control IgG (MG3-35; BioLegend, #401317) 12 
Alexa647-conjugated TRA-1-60 (TRA-1-60-R; BioLegend, #330606) 13 
Alexa647-conjugated isotype control IgM (MM-30; BioLegend, #401618) 14 
Anti-PAX6 antibody (PRB-278P; BioLegend, #901301) 15 
Anti-PAX6 antibody (AD2.35; Santa Cruz Biotechnology, #sc-53108) 16 
Anti-p63 antibody (4A4; Santa Cruz Biotechnology, #sc-8431) 17 
Anti-CHX10 antibody (N-18; Santa Cruz Biotechnology, #sc-21690) 18 
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Anti-MITF antibody (C5; Exalpha Biologicals, #X1405M) 1 
Anti-TUBB3 antibody (T2200; Sigma-Aldrich, #T2200)  2 
Anti-SOX10 antibody (N-20; Santa Cruz Biotechnology, #sc-17342) 3 
Anti-p75 antibody (ME20.4; Advanced Targeting Systems, #AB-N07) 4 
Anti--Crystallin antibody (SPA-224; Stressgen Biotechnologies, #SPA-224) 5 
Anti-K12 antibody (N-16; Santa Cruz Biotechnology, #sc-17098) 6 
Anti-K3/76 antibody (AE5; PROGEN Biotechnik, #61807) 7 
Anti-MUC1 antibody (M4H2; Abcam, #ab10120) 8 
Anti-MUC16 antibody (OV185:1; Abcam, #ab697) 9 
Alexa Fluor 488 donkey anti-Rabbit IgG (H+L) (Life Technologies, #A21206) 10 
Alexa Fluor 594 donkey anti-Rabbit IgG (H+L) (Life Technologies, #A21207) 11 
Alexa Fluor 568 donkey anti-Goat IgG (H+L) (Life Technologies, #A11057) 12 
Alexa Fluor 488 donkey anti-Mouse IgG (H+L) (Life Technologies, #A21202) 13 
Alexa Fluor 568 donkey anti-Mouse IgG (H+L) (Life Technologies, #A10037) 14 
4% (wt/vol) Paraformaldehyde phosphate buffer solution (PFA) (Wako, #163-20145) 15 
Cellstain® Hoechst 33342 Solution (Wako, #346-07951) 16 
Triton X-100 (SIGMA, #T8787-100ML) 17 
Normal donkey serum (Jackson ImmunoResearch, #017-000-121) 18 
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TBS powder (TakaraBio, #T903) 1 
StemFitTM medium (Ajinomoto, #AK02 or AK03) 2 
AccutaseTM (Life Technologies, #A11105-01) 3 
TrypLETM Select (Life Technologies, #12563-029) 4 
0.5 mM EDTA solution (Nacalai tesque, #13567-84) 5 
Trypan Blue Stain 0.4% (Thermo Fisher Scientific, #T10282) 6 
KGF (R&D, #251-KG or Wako, #112-00813) 7 
Y-27632 (Wako, #034-24024) 8 
B-27 supplement (Life Technologies, #17504-044) 9 
LN511E8 fragment (i-Matrix-511; Nippi, #892011) 10 
GMEM (Life Technologies, #11710-035) 11 
Penicillin-Streptomycin solution (Life Technologies, #15140-122) 12 
Non-essential amino acids (Life Technologies, #11140-050) 13 
Sodium pyruvate (Life Technologies, #11360-070) 14 
Knockout serum replacement (KSR) (Life Technologies, #10828-028) 15 
2-mercaptoethanol (2-ME) (Life Technologies, #21985-023) 16 
Caution: 2-ME is toxic and flammable. Wear gloves and handled it carefully. 17 
Monothioglycerol (replacement for 2-ME) (Wako, #195-15791) 18 
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CnT-PR [w/o; EGF and FGF2] (CELLnTEC, #CnT-PR-EF) 1 
DMEM/F-12 [1:1] (Life Technologies, #11320-033) 2 
DMEM without glutamine and Nutrient Mixture F-12 Ham (3:1) (Life Technologies, #10313-3 
021, #11765-054) 4 
Hydrocortisone succinate (Wako, #080-05581) 5 
3,3',5-Triiodo-L-thyronine sodium salt (MP Biomedicals, #194585) 6 
Cholera toxin (List Biological Laboratory, #100B) 7 
Caution: Cholera toxin is potentially harmful. Wear gloves and handle it carefully in a biosafety 8 
cabinet. 9 
Bovine transferrin HOLO form (Life Technologies, #11107-018) 10 
L-glutamine (Life Technologies, #25030-081) 11 
Insulin transferrin selenium solution (Life Technologies, #41400-045) 12 
FBS (Japan Bio Serum, #15-001-JBS or Life Technologies, #12483-020) 13 
STEM-CELLBANKER (TakaraBio, #CB046) 14 
DPBS, no calcium, no magnesium (Life Technologies, #14190-144) 15 
 16 
Equipment 17 
Cell sorter (BD Biosciences, FACSAriaII) 18 
16 
 
CO2 Incubator (Panasonic, #MCO-20AIC) 1 
Bio-clean bench (Panasonic, #MCV-B131F) 2 
Bio-safety cabinet (ESCO, #JA2-4A7) 3 
Ultra-low freezer (Panasonic, #MDF-U33V) 4 
Ultra-low freezer (Panasonic, #MDF-C2156VAN) 5 
Fluorescent microscope (Carl Zeiss, Axio Observer. D1) 6 
Fluorescent microscope (Thermo Fisher Scientific, EVOS®) 7 
Stereomicroscope (Olympus, #SZ61) 8 
Centrifuge machine (TOMY, #LC-230) 9 
Culture plate 6-well, 12-well (Corning, #353046, #353043) 10 
Culture insert 12-well (FALCON, #353180) 11 
UpCell® 6-well plate (CellSeed, #CS3004) 12 
STEMFULLTM tube (Sumitomo Bakelite, #MS-90150) 13 
Cell Strainer (40 µm) (Corning, #352340) 14 
Automated cell counter (Thermo Fisher Scientific, Countess®) 15 
PVDF membrane filter (Millipore, #SVWG04700) 16 
Cell Scraper (Sumitomo Bakelite, #MS-93100) 17 
Falcon 50-mL polypropylene conical tube (FALCON, #352070) 18 
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Falcon 15-mL polypropylene conical tube (FACLON, #352096) 1 
PermaFluorTM Aqueous Mounting Medium (Thermo Fisher Scientific, # TA-030-FM). 2 
 3 
REAGENT SET-UP 4 
Differentiation medium (DM)  GMEM supplemented with 10% (vol/vol) knockout serum 5 
replacement (KSR), 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 2 mM L-6 
glutamine, 1% (vol/vol) penicillin-streptomycin solution, and 55 M 2-mercaptoethanol (2-ME) 7 
or monothioglycerol (a replacement for 2-ME) 32. 8 
The medium should be stored at 4 °C and used within two weeks. 9 
Caution: 2-ME is toxic and flammable. Wear gloves and handle it carefully. 10 
KGF frozen stock Dissolve 1.0 mg of KGF in 50 mL of PBS containing 0.1% (wt/vol) human 11 
serum albumin and store at 50-100 µL/tube (20 µg/mL) at -80°C or -30°C for up to three 12 
months. 13 
Y-27632 frozen stock Dissolve 25 mg of Y-27632 in 7.4 mL of PBS and store at 50 µL/tube (10 14 
mM) at -30°C or -80°C for up to six months. 15 
Corneal differentiation medium (CDM) Prepare DM and CnT-PR [w/o EGF and FGF2] (1:1) 16 
containing 10-20 ng/mL KGF, 10 µM Y-27632, and 1% (vol/vol) penicillin-streptomycin 17 
solution. Add KGF and Y-27632 to the basal medium of the CDM (w/o KGF and Y-27632) 18 
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before use. The basal medium should be stored at 4 °C and used within two weeks. 1 
Corneal epithelium maintenance medium (CEM) Prepare DMEM/F-12 [1:1] containing 2% 2 
(vol/vol) B-27 supplement, 10-20 ng/mL KGF, 10 µM Y-27632, and 1% (vol/vol) penicillin-3 
streptomycin solution. Add B-27 supplement, KGF, and Y-27632 to the basal medium of CEM 4 
(w/o B-27, KGF, and Y-27632) before use. The basal medium should be stored at 4°C and used 5 
within two weeks. 6 
KCM medium Prepare DMEM without glutamine and Nutrient Mixture F-12 Ham (3:1) 7 
supplemented with 5% (vol/vol) FBS, 0.4 µg/mL hydrocortisone succinate, 2 nM 3,3',5-triiodo-8 
L-thyronine sodium salt, 1 nM cholera toxin, 2.25 µg/mL bovine transferrin HOLO form, 2 mM 9 
L-glutamine, 0.5% (vol/vol) insulin transferrin selenium solution, and 1% (vol/vol) penicillin-10 
streptomycin solution. The medium should be stored at 4 °C and used within three weeks. 11 
Corneal epithelium-maturation medium (CMM) Prepare KCM medium containing 10-20 12 
ng/mL KGF and 10 µM Y-27632. Add KGF and Y-27632 to the KCM before use. The basal 13 
medium (KCM medium) should be stored at 4°C and used within three weeks. 14 
 15 
PROCEDURE 16 
Human iPS cell maintenance and subculture: Plate coating TIMING ~3 h  17 
CRITICAL The use of an appropriate human iPS cell clone is important to achieve successful 18 
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ocular surface epithelial cell differentiation. As discussed earlier, we found clone 201B7 to be 1 
suitable for the protocol described here, however other clones conceivably could be used with 2 
appropriate modifications to the protocol. 3 
1. Coat new 6-well culture plates with LN511E8 (i-Matrix) at 0.5 µg/cm2 in 1.5 mL of PBS by 4 
incubation at 37°C for 2 hr. 5 
2. Add 0.7 mL of StemFitTM medium to the culture plates. 6 
3. Remove the mixed solution and immediately add 1.5 mL of StemFitTM medium containing 10 7 
µM Y-27632. 8 
Critical step: Do not allow the surface of the culture plates to dry. Add StemFitTM medium 9 
immediately after the removal of the coating solution. 10 
4. Incubate plates at 37°C in 5% CO2 for around 15 min whilst preparing human iPS cells, as 11 
described in steps 5-12. 12 
Human iPS cell maintenance and subculture: Human iPS cell seeding from frozen cell stock 13 
TIMING 7 d 14 
5. Add 5 mL of StemFitTM medium to a 15-mL conical tube.  15 
6. Take a frozen stock of 2 × 105 of human iPS cells, preserved in 0.2 mL STEM-16 
CELLBANKER from a liquid nitrogen tank or an ultra-deep freezer (-150°C) and thaw in a 17 
water bath at 37°C. 18 
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Critical step: Do not leave the frozen cells in the water bath for too long, as this could cause cell 1 
death. 2 
7. Immediately after thawing, transfer the cell suspension into 5 mL of StemFitTM medium in the 3 
15-mL conical tube. 4 
Critical step: Do not perform manual pipetting more than twice, to reduce the risk of cell 5 
damage.  6 
8. Centrifuge the cells at 160 × g for 5 min at room temperature (20-28°C). 7 
9. Remove the supernatant. 8 
10. Add 0.5 mL of StemFitTM medium and pipette the cells. 9 
11. Count the collected cells using a Countess® Machine immediately after staining with Trypan 10 
blue (settings for Countess®: sensitivity = 5, minimum size = 8, maximum size = 30, circularity 11 
= 75). 12 
12. Seed cells on the LN511E8 coated 6-well culture plates (from Step 4) at 65,000 cells/well. 13 
Critical step: Spread the cells evenly after seeding. 14 
13. Incubate the plates overnight at 37°C in 5% CO2.  15 
14. The next day, replace the medium with fresh StemFitTM medium without Y-27632 and 16 
incubate at 37°C in 5% CO2 up to day 7. The medium should be changed every two days. 17 
TROUBLESHOOTING 18 
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Human iPS cell maintenance and subculture: Cell passaging TIMING at least 7-21 d 1 
15. Prepare LN511E8-coated 6-well culture plates as described in Steps 1-4. 2 
16. Remove the culture medium from human iPS cells. 3 
17. Wash the cells once with 1 mL of PBS. 4 
18. Add 300 µL of dissociation solution (50% (vol/vol) TrypLE Select and 50% (vol/vol) 0.5 5 
mM EDTA solution) and incubate for 4-5 min at 37°C. 6 
19. Remove the dissociation solution. 7 
Critical step: Perform this step carefully because the human iPS cells are still attached to the 8 
culture plates at this point. 9 
20. Wash the cells once with 2 mL of PBS and then add 1 mL of StemFit™ medium containing 10 
10 µM Y-27632. 11 
21. Detach the cells from the culture plates mechanically using a Cell Scraper. 12 
22. Pipette the cells about 10 times with a 200- or 1000-µL micropipette and transfer the 13 
dissociated ones to a 1.5-mL tube. 14 
23. Count the collected human iPS cells using a Countess® Machine immediately after staining 15 
with Trypan blue (settings for Countess®: sensitivity = 5, minimum size = 8, maximum size = 16 
30, circularity = 75). 17 
24. Seed the cells on LN511E8 coated 6-well culture plates (from Step 15) at 13,000 cells/well. 18 
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Critical step: Spread out the cells evenly after seeding. 1 
25. Incubate overnight at 37°C in 5% CO2.  2 
26. The next day, replace the medium with fresh StemFitTM medium without Y-27632 and 3 
incubate at 37°C in 5% CO2 up to day seven. The medium should be changed every two days. 4 
 CRITICAL STEP : In modified protocols iPS cells might have been maintained in conditions 5 
other than those described above (for example, using co-culture with MEF feeder layers or in 6 
other feeder-less culture systems). If this is the case, after the removal of the feeder cells the 7 
dissociated iPS cells should be seeded in the StemFitTM/LN511E8 culture system at 13,000 8 
cells/well and passaged at least three to four times to adapt to the changed conditions. 9 
CRITICAL STEP: We used human iPS cells before passage 40 for our differentiation experiments, 10 
but we have no definitive data regarding the influence of cell passage number on iPS cells and 11 
their differentiation. 12 
Differentiation culture: Preparing human iPS cells for differentiation culture TIMING 10 d 13 
27. Coat a 6- or 12-well culture plate with LN511E8 at 0.5 µg/cm2 as described in Steps 1-4. 14 
28. Harvest human iPS cells by the same method used for their passaging in steps 15-26. 15 
29. Seed the dissociated cells on 6-well plates at 1500-6000 cells/well, or on 12-well plates at 16 
500-2000 cells/well in 1.5 mL (6-well plate) or 0.6-mL (12-well plate) of StemFitTM medium 17 
containing 10 M Y-27632. 18 
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Critical step: The initial seeding density is important. To generate SEAMs, a relatively low cell 1 
density (e.g. 1500-4500 cells/6-well plate) is recommended. This will help to avoid the fusion of 2 
colonies. We found that to successfully generate corneal epithelial progenitor cells a relatively 3 
high cell density (e.g. 4500-6000 cells/6-well plate) is required. The high seeding density, 4 
however, is accompanied by the associated risk that colonies might fuse, which makes it 5 
difficult to obtain regular concentric multiple cellular zones within all SEAMs. For neural crest 6 
induction in SEAM zone-2, a lower cell density (e.g. 1000-2000 cells/6-well plate) is suitable. 7 
30. Incubate overnight at 37°C in 5 % CO2. 8 
31. The next day, 24 hrs after seeding, replace the medium with fresh StemFitTM medium 9 
without Y-27632. 10 
32. Incubate the plates at 37°C in 5% CO2 (for 10 days in total). Change the medium every two 11 
days before day 7 and every day thereafter. 12 
Differentiation culture: Ocular cell differentiation culture (Day 0-) TIMING 4 w 13 
33. After 10 days in culture in StemFitTM medium, replace it with DM and use volumes of 2 mL 14 
(in a 6-well plate) or 1 mL (in a 12-well plate) (Day 0).  15 
34. Incubate at 37°C in 5% CO2 for 4 weeks, changing the medium every 2-3 days to achieve 16 
three changes per week. 17 
At 3-4 weeks, approximately 60-70% of human iPS cell colonies should appear as circular 18 
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colonies comprised of 3-4 concentric zones8. As mentioned previously, this type of colony has 1 
been termed a “SEAM” -- a self-formed ectodermal autonomous multi-zone8. To verify the 2 
existence of the ocular cell lineages in each zone, immunostaining for ocular cell makers is 3 
useful (BOX 1). Within a SEAM cells in the third zone from the center have characteristics of 4 
ocular surface ectodermal cells (PAX6/p63-double-positive phenotype) and the ability to 5 
differentiate into functional corneal epithelial cells.  6 
TROUBLESHOOTING 7 
Differentiation culture: CDM culture (Day 28-) TIMING 4 w 8 
35. After 4 weeks of incubation in DM, replace the medium with either 2 mL (in a 6-well plate) 9 
or 1 mL (in a 12-well plate) of CDM. 10 
36. Incubate the plates for an additional 4 weeks at 37°C in 5% CO2 (8 weeks culture in total). 11 
The medium should be changed every 2-3 days (around 3 times per week). 12 
Optional: To encourage retinal cell differentiation, change the medium to CEM, rather than 13 
CDM, at day 28. After incubation in CEM for an additional 2 to 3 weeks (i.e. 6 to 7 weeks of 14 
culture in total) pigmented retinal pigment epithelium (RPE)-type cells can be observed in zone 15 
2 of the SEAM. 16 
Differentiation culture: Manual pipetting to remove non-epithelial cells (Day 49) TIMING 17 
1d 18 
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37. At around three weeks of incubation in CDM (i.e. after seven weeks of culture in total) 1 
perform manual pipetting using a PIPETMANTM (1000 µL or 200 µL) on a clean bench to 2 
remove non-epithelial like cells (e.g. neuronal-type cells, retinal-type cells, and/or lens-type 3 
cells) from zones 1 and 2 of the SEAM. Cells in zones 1 and 2 of the SEAM adhere to the 4 
culture plates less strongly than cells in zones 3 and 4. Because of this, manual pipetting can be 5 
used to rinse away zone 1-2 cells from the SEAM, whilst leaving zone 3-4 cells intact. To do 6 
this, simply aspirate some CDM medium from the culture dish and flush it over the SEAM. This 7 
can either be carried out using 150-200 µl of medium and a 200 µl PIPETMANTM or 500-800 8 
µl of medium and a 1000 µl PIPETMANTM. Typically, one wash is sufficient using the larger 9 
pipette, whereas two or three repeats tend to be needed using the smaller one. In both cases, the 10 
pipette tip is larger than the SEAM. Depending on seeding density and closeness of the SEAMs, 11 
the larger pipette can often treat several SEAMs in one action. The procedure seems to work 12 
best if the pipette is angled away from 90º to the surface of the SEAM. 13 
CRITICAL STEP: Pipetting causes the yield of corneal epithelial-type cells for subsequent cell 14 
sorting to be higher than it would have been had manual pipetting not been carried out. 15 
CRITICAL STEP: Caution: Some practice is required here. Do not perform the pipetting too 16 
vigorously; otherwise, it will detach not only zone 1 and 2 cells, but those in zones 3 and 4 as 17 
well. Also, take care that the pipette tip does not actually touch the SEAM. 18 
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CRITICAL STEP: A stereomicroscope is useful, but not essential, for performing this step. 1 
 2 
38. After pipetting, discard the medium containing the detached cells, and add fresh CDM to the 3 
culture plate.  4 
39. Incubate the plates for one additional week in CDM for eight weeks of culture in total. 5 
Differentiation culture: CEM culture (Day 56-) TIMING at least 2-4 w 6 
40. After CDM culture for four weeks (i.e. eight weeks overall), change the medium to 2 mL (in 7 
a 6-well plate) or 1 mL (in a 12-well plate) of CEM. 8 
41. Incubate the plates for between two weeks (i.e. 10 weeks in total) and eight weeks (i.e. 16 9 
weeks in total) at 37°C in 5 % CO2. As before, the medium should be changed every 2-3 days 10 
(i.e. three times per week). In most case, 12 weeks is suitable for subsequent cell sorting. 11 
FACS for isolating corneal epithelial stem/progenitor cells (Day 70-): Cell staining with 12 
antibodies. TIMING at least 3 h 13 
42. After CEM culture, wash the differentiated human iPS cells once with PBS. 14 
43. Add 1mL (in a 12-well plate) or 2 mL (in a 6-well plate) of AccutaseTM and incubate for 45 15 
min at 37°C.  16 
44. Perform pipetting several times using a PIPETMANTM (1000 µL) to dissociate the cells and 17 
incubate, once more, for 15 min at 37°C.  18 
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45. Collect and re-suspend the dissociated cells in ice-cold KCM medium in a STEMFULLTM 1 
15-mL tube. 2 
46. Filter the cells using a Cell Strainer (40 µm) and count the cells. 3 
47. Centrifuge at 280 × g for 8 min at room temperature. 4 
48. Aspirate the supernatant and re-suspend the cells in ice-cold KCM containing FITC-5 
conjugated SSEA-4 (MC813-70), PE-conjugated CD104 (ITGB4; 58BX4), and Alexa647-6 
conjugated TRA-1-60 (TRA-1-60R) antibodies. For isotype control, stain cells with FITC-, PE-, 7 
or Alexa647-conjugated non-specific isotype antibodies (for SSEA-4, ITGB4 and TRA-1-60, 8 
respectively). For colour compensation on flow cytometry, to be performed according to 9 
manufacturer’s protocols, stain cells with each single antibody against SSEA-4, ITGB4 and 10 
TRA-1-60. The cell density should be less than 1 × 107 cells/mL. 11 
49. Incubate the cells for 1 hr at 4°C, agitating every 20 min. 12 
50. Wash the cells twice with PBS. 13 
51. Re-suspend the cells in PBS by filtration using a Cell Strainer (40 µm).  14 
TROUBLESHOOTING 15 
FACS for isolating corneal epithelial stem/progenitor cells: Cell sorting TIMING at least 16 
2.5 h 17 
52. Set up the FACSAriaII machine according to manufacturer’s protocol. 18 
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53. Subject isotype antibody stained samples and single colour-stained samples sequentially to 1 
the FACSAriaII and acquire the data. 2 
54. Perform compensation between the detectors for FITC, PE, and Alexa647 using each of the 3 
single-stained cells according to manufacturer’s protocols applicable to FACSAriaII. 4 
CRTICAL STEP: A positive region for each antibody staining needs to be defined, and this is 5 
defined as a region that contains almost no cells (e.g. less than 0.3%) stained with the 6 
corresponding isotype control antibody. 7 
55. Analyze the triple colour-stained cells according to manufacturer’s protocols of FACSAriaII. 8 
Briefly, a Alexa647 negative region (TRA-1-60 negative cell population) is selected, after which 9 
the population is analyzed by FITC (SSEA-4) and PE (ITGB4) using dot plot. 10 
TROUBLESHOOTING 11 
56. Sort the SSEA-4+/ITGB4+/TRA-1-60- population (i.e. the human iPS cell-derived corneal 12 
epithelial cell (human iCEC) fraction) to 8 mL of KCM in a STEMFULLTM 15-mL tube.  13 
Typically, in TRA-1-60 negative cells, 5-20% of the cells are identified as the human iCEC 14 
fraction. 15 
TROUBLESHOOTING 16 
57. Collect human iCECs by centrifugation at 280 × g for 8 min at room temperature. 17 
58. Re-suspend the cells in CEM on ice. 18 
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TROUBLESHOOTING 1 
Fabrication of human iCEC sheet (Day 70)  2 
59. At this stage, two options exist for the fabrication of human induced corneal epithelial cell 3 
(iCEC) sheets. Follow Option A for cultivation on a temperature-responsive culture plate or 4 
Option B for longer-term culture on a cell culture insert. 5 
Option A. Cultivation on a temperature-responsive culture plate and cell harvest. TIMING 6 
10-22 d 7 
i. Coat a 6-well UpCell® plate with LN511E8 at 0.25-0.5 g/cm2 and incubate at 37°C for 60 8 
min. 9 
ii. Seed FACS-sorted SSEA-4+/ITGB4+/TRA-1-60- cells (i.e. human iCECs) on the 6-well 10 
UpCell® plate at 1.5-6.0 ×105 cells/well in CEM. 11 
iii. Incubate the plates at 37°C in 5% CO2 for 5-12 days until cells reach 100% confluence. 12 
Change the medium every two days. 13 
iv. After cells reach confluence, replace the medium with CMM. 14 
v. Incubate the cells in CMM for a further 3-10 days at 37°C in 5% CO2 to allow stratification. 15 
We find that the procedure works as long as the CMM incubation is within the 3-10 day 16 
window.  17 
Change the medium every two days. 18 
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vi. Incubate the UpCell® plate at 20°C for 30 min. 1 
vii. Place a PVDF membrane with a diameter of 25-mm and a 15-mm hole in the centre on the 2 
cell sheet to act as a carrier as described in detail in reference 33. 3 
viii. Harvest the cell sheet using fine surgical tweezers under a stereomicroscope. Specifically, 4 
detach the peripheral part of the cell sheet from the dish and place it on the membrane. 5 
Subsequent to this, it is straightforward to harvest the cell sheet by simply lifting the membrane 6 
with the cell sheet using surgical tweezers. 7 
TROUBLESHOOTING 8 
Option B. Insert culture (for longer-term culture or for promoting maturation) TIMING 10-9 
80 d 10 
i. Coat a 12-well culture insert with LN511E8 at 0.25-0.5 g/cm2 and incubate at 37°C for 60 11 
min. 12 
ii. Seed FACS-sorted SSEA-4+/ITGB4+/TRA-1-60- cells (i.e. human iCECs) on the 12-well 13 
culture inserts at 0.4-1.5 × 105 cells/well in CEM. 14 
iii. Incubate the cell culture inserts at 37°C in 5% CO2 for 5-12 days until cells reach 100% 15 
confluence. The medium should be changed every two-to-three days. For longer-term culture, 16 
maintain human iCECs on cell culture inserts up to 10 weeks in CEM changing the medium 17 
every two-to-three days. 18 
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v. To promote the maturation of the confluent cells, change the medium to CMM approximately 1 
one week before the culture is completed. Although CMM culture promotes maturation, it is not 2 
essential for stratification. 3 
 4 
Timing 5 
The entire protocol from the initial preparation of human iPS cells to the fabrication of corneal 6 
epithelial cell sheets can take a total of 102 days minimum, but most often, we find that 120+ 7 
days is required. 8 
Steps 1-4, Human iPS cell maintenance and subculture: Plate coating: 3 h  9 
Steps 5-14, Human iPS cell maintenance and subculture: Human iPS cell seeding from frozen 10 
cell stock : 7 d 11 
Steps 15-26, Human iPS cell maintenance and subculture: Cell passaging: at least 7-21 d 12 
Steps 27-32, Differentiation culture: Preparing human iPS cells for differentiation culture: 10 d 13 
Steps 33-34, Differentiation culture: Ocular cell differentiation culture (Day 0-): 4 w 14 
Steps 35-36, Differentiation culture: CDM culture (Day 28-): 4 w 15 
Steps 37-39, Differentiation culture: Manual pipetting to remove non-epithelial cells (Day 49): 1 16 
d 17 
Steps 40-41, Differentiation culture: CEM culture (Day 56-): at least 2-8 w 18 
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Steps 42-51, FACS for isolating corneal epithelial stem/progenitor cells (Day 70-): Cell staining 1 
with antibodies: at least 3 h 2 
Steps 52-58, FACS for isolating corneal epithelial stem/progenitor cells: Cell sorting: at least 3 
2.5 h 4 
Step 59 Option A, Fabrication of human iCEC sheet: Cultivation on a temperature-responsive 5 
culture plate and cell harvest: 10-22 d 6 
Step 59 Option B, Fabrication of human iCEC sheet: Insert culture (for longer-term culture or 7 
for promoting maturation): 10-80 d 8 
BOX1, Recommended method for the characterization of cells in a SEAM: 2-7 d 9 
BOX2, Recommended method for validation of human iPS cell-derived corneal epithelial cell 10 
sheets: 2-6 d 11 
See Table 2 for Troubleshooting guidance.  12 
 13 
Anticipated Results 14 
Multi-zonal colony (SEAM) formation By four weeks of differentiation, colonies with 15 
concentric multi-cellular zones (typically 3-4 zones as shown in Fig. 3A) will have generated 16 
spontaneously. For the validation of ocular surface epithelial induction (in zone 3) PAX6 and 17 
p63 double-staining is useful (Fig. 3B). When double-positive cells are detected at three-to-four 18 
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weeks in the peripheral region of the colony and at 10 weeks overall, the method is deemed to 1 
have worked successfully. 2 
Fabrication of corneal epithelial cell sheets. After the removal of non-epithelial cells from the 3 
SEAM by pipetting, those remaining at 12 weeks of differentiation are subjected to FACS (Fig. 4 
4A, B). Flow cytometric analysis at this time typically shows that 5-20% of TRA-1-60 negative 5 
cells are human iCECs (i.e. SSEA-4+/ITGB4+ cells) (Fig. 4C). The FACS-sorted human iCECs 6 
typically exhibit a small cobblestone-like morphology by phase contrast microscopy and when 7 
observed by immunostaining after 2 to 3 weeks of culture in CEM and CMM have become 8 
stratified into two to four layers. The stratified cell sheets express K12 and PAX6 throughout all 9 
cell layers, as well as MUC16 (on the sheet’s surface) and p63 (strongly in the basal region) 10 
(Fig. 5). 11 
BOX1 12 
Recommended method for the characterization of cells in a SEAM Timing: 2-7 d 13 
1. Fix differentiated human iPS cells after four weeks (or two weeks for neural crest 14 
staining) of differentiation culture in 4% (wt/vol) PFA at room temperature. Fix for 20 15 
min. For CHX10 and MITF staining, fix cells that had been differentiated by the retinal 16 
differentiation protocol (shown in Step 36). 17 
2. Wash the cells with Tris-buffered saline (TBS) three times for 10 min. 18 
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3. Incubate the cells in TBS containing 5% (vol/vol) normal donkey serum and 0.3% 1 
(wt/vol) Triton X-100 (blocking buffer) for 1 hr at room temperature for blocking of 2 
non-specific binding and cell permeabilization. For the mouse monoclonal PAX6 3 
antibody (AD2.35), cell permeabilization should be performed at 4°C for three days. 4 
4. Incubate the cells with each of following primary antibodies; PAX6 (PRB-278P, 5 
BioLegend, 1:300), p63 (4A4, Santa Cruz Biotechnology, 1:200), -Crystallin (SPA-6 
224, Stressgen Biotechnologies, 1:200), TUBB3 (T2200, Sigma-Aldrich, 1:100), 7 
SOX10 (N20, Santa Cruz Biotechnology, 1:100), p75 (ME20.4, Advanced Targeting 8 
Systems, 1:100), CHX10 (N-18, Santa Cruz Biotechnology, 1:500) and MITF (C5, 9 
Exalpha Biologicals, 1:2000) at 4°C overnight or at room temperature for 3 hrs. For the 10 
mouse monoclonal PAX6 antibody (AD2.35, Santa Cruz Biotechnology, 1:60), incubate 11 
cells at 4°C for 3 days. Dilute antibodies with TBS containing 1% (vol/vol) normal 12 
donkey serum and 0.3% (wt/vol) Triton X-100 (dilution buffer). 13 
5. Wash the cells 3 times with TBS for 5 min. 14 
6. Incubate cells with the secondary antibody, which corresponds to the primary antibody. 15 
Use a 1:200 diluted with dilution buffer for 1 hr at room temperature in the dark. 16 
7. Wash the cells 3 times with TBS for 5 min. 17 
8. Repeat Steps 3-7 for double immunostaining. 18 
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9. Stain cells (for nuclear staining) with Hoechst 33342 for 10 min at room temperature 1 
under protection from light. 2 
10. Wash the cells 3 times with TBS for 5 min. 3 
11. Mount the cells with PermaFluorTM and observe by fluorescence microscopy. 4 
BOX 2 5 
Recommended method for validation of human iPS cell-derived corneal epithelial cell 6 
sheets Timing: 2-6 d 7 
1. Embed human iCEC sheets in OCT compound and store at -80°C. 8 
2. Cut 10 μm-thick cryostat sections. 9 
3. Dry the frozen sections for at least 2 hrs at room temperature. 10 
4. Wash the slides once with TBS. (For p63 staining, the cells should be fixed with cold 11 
methanol for 1 hr before washing with TBS). 12 
5. Incubate the slides in blocking buffer for 1 hr at room temperature. 13 
6. Incubate the slide with each of following antibodies; PAX6 (PRB-278P, BioLegend, 14 
1:300), p63 (4A4, Santa Cruz Biotechnology, 1:200), K12 (N16, Santa Cruz 15 
Biotechnology, 1:200), K3 (AE5, PROGEN Biotechnik, 1:200), MUC1 (M4H2, Abcam, 16 
1:200) and MUC16 (OV185:1, Abcam, 1:200) at 4°C overnight or at room temperature 17 
for 3 hrs. Antibodies should be diluted with dilution buffer. 18 
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7. Wash the slides 3 times with TBS for 5 min. 1 
8. Incubate the slides with the secondary antibody, which corresponds to the primary 2 
antibody (1:200 diluted with dilution buffer) for 1 hr at room temperature under 3 
protection from light. 4 
9. Wash the cells with TBS 3 times at room temperature. 5 
10. Stain with Hoechst 33342 for 10 min at room temperature under protection from light. 6 
11. Wash the cells three times with TBS for 5 min. 7 
12. Mount the cells with PermaFluorTM and observe by fluorescence microscopy. 8 
Table 1: Antibodies to verify the existence of ocular cell lineages in each zone 9 
Zone Cell type Markers References 
1 Neuronal cell TUBB3 (T2200, Sigma-Aldrich, 1:100) 8), 20) 
2 (early 
period) Neural crest 
p75 (ME20.4, Advanced Targeting Systems, 1:100)/ 
SOX10 (N20, Santa Cruz Biotechnology, 1:100) 
8), 24)
 
2 (inner 
side) Neuro retinal cell CHX10 (N-18, Santa Cruz Biotechnology, 1:500) 
8), 23)
 
2 (outer 
side) 
Retinal pigment 
epithelial cell 
MITF (C5, Exalpha Biologicals, 1:2000) 8), 23) 
2-3 
Lens cell 
PAX6 (AD2.35, Santa Cruz Biotechnology, 1:60)/  (SPA-224, Stressgen Biotechnologies, 
1:200) 
25), 26)
 
3 Ocular surface 
epithelial cell 
PAX6 (PRB-278P, BioLegend, 1:300)/ 
p63 (4A4, Santa Cruz Biotechnology, 1:200) 
8), 18), 19)
 
4 Epithelial cell p63 (4A4, Santa Cruz Biotechnology, 1:200) 21), 22) 
 10 
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Table 2. Troubleshooting Table 1 
Step Problem Possible reason Solution 
Step 14 
and 26 
Human iPS cells are not 
in a good condition or in 
an unstable condition. 
1) Cells are 
differentiated 
To verify whether or not human iPS cells have 
maintained an undifferentiated status, examine 
the expression of pluripotent stem cell markers, 
TRA-1-60 and SSEA-4 by immunostaining. If 
cells have differentiated, restarting the iPS cell 
culture is recommended. 
 
2) The duration of Y-
27632 treatment is 
too short or too long.  
Incubate human iPS cells in Y-27632-
containing StemFitTM medium for 24 to 30 hr 
after cell seeding. An appropriate period of Y-
27632 treatment is essential for the survival of 
human iPS cells during cell passages. 
Step 26 The colony forming 
efficiency (CFE) of 
human iPS cells at cell 
passaging is too low or 
too high. (N.B. The CFE 
of the 201B7 human iPS 
cell line is around 6-14% 
in our experiments). If a 
satisfactory outcome is 
not achieved, it is likely 
to reflect changes in cell 
characteristics during 
passaging. If 
subsequent SEAM 
formation and corneal 
epithelial cell expansion 
is not achieved, 
restarting the iPS cell 
culture is recommended. 
1) LN511E8-coating 
on culture plates is 
insufficient 
Do not allow the surface of the culture plates to 
dry at steps 3 and 15. Add StemFitTM medium 
immediately after the removal of the coating 
solution.  
 
2) Human iPS cells 
are damaged by 
enzymatic treatment 
or mechanical 
harvesting at cell 
passaging 
Keep the treatment time with the dissociation 
solution brief at around 4-5 min, and gently 
harvest human iPS cells using the Cell Scraper 
at cell passaging. 
 
3) The duration of Y-
27632 treatment is 
too short or too long.  
Incubate human iPS cells in Y-27632-
containing StemFitTM medium for 24 hr to 30 hr 
after cell seeding. An appropriate treatment with 
Y-27632 is essential to ensure survival of 
human iPS cells during passaging. 
38 
 
Step 34 Cells do not generate 
zone 3, nor a typical 
SEAM structure by 4 
weeks of differentiation 
culture. 
1) The cell density is 
not appropriate. 
Seed human iPS cells at several cell densities 
ranging from 1500 to 6000 cells/well (6-well 
plate) or 500 to 2000 cells/well (12-well plate) 
because the seeding density has a significant 
influence over the formation of a SEAM and the 
induction of zone 3. When the seeding density 
is high, immunostaining for PAX6 and p63 is 
useful to detect zone 3 because it can become 
difficult to identify by microscopy alone. 
  
2) The human iPS 
cell clone might not 
be appropriate for 
conditions in the 
protocol we describe 
here. 
The best results were achieved with clone 
201B7, and the protocol might need 
optimization for other clones. 
Step 51 The yield of cells after 
antibody staining is low. 
Cells might have 
been lost in collection 
tubes during antibody 
staining. 
Use low absorbing tubes (StemFullTM) and 
serum containing medium, CMM. This is 
recommended to prevent cell absorption to 
tubes during incubation with antibodies.  
Step 55 The ratio of the corneal 
epithelial cell fraction is 
low (i.e. around 5% or 
lower) based on FACS 
analysis. In this case, 
restarting the 
differentiation culture is 
strongly recommended, 
although possible 
explanations and 
solutions are indicated 
here. 
1) The culture period 
is too short.  
Prolong the culture period to 12 weeks. In some 
cases, even 10 weeks is too brief to obtain a 
sufficient amount of human iCECs.  
 
2) Manual pipetting of 
cells outside SEAM 
zone 3 is not 
sufficient. 
Perform manual pipetting carefully to remove 
the non-epithelial like cells that reside in zone 1 
and 2 of the SEAM. Even though manual 
pipetting is not essential to obtain human 
iCECs, it greatly improves the efficiency of the 
final corneal epithelial-like cell yield. 
Step 56 The yield of sorted 
human iCECs is low 
after FACS. 
Sorted human iCECs 
might have been lost 
in collection tubes.  
Use low absorbing tubes (StemFullTM) and 
serum containing medium, CMM. This is 
recommended to prevent cell absorption to 
tubes. 
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Step 59 Human iCECs do not 
form epithelial cell 
sheets. 
1) There is a low cell 
density at human 
iCEC seeding. 
Seed human iCECs at an appropriate cell 
density as described in step 59. A low seeding 
density tends to promote EMT (epithelial-to-
mesenchymal transition) or the proliferation of 
cells without corneal epithelial characteristics. 
When sufficient numbers of human iCECs, as 
shown in step 59, are not collected after FACS, 
we recommend redoing the FACS. 
 
2) The human iCEC 
shrinks after reaching 
confluence in CEM. 
Change CEM to CMM before reaching 70-80% 
confluence.  
  
3) The culture period 
is too short. 
To ensure that human iCECs become fully 
stratified they should be cultivated, first in CEM 
and then CMM, for at least 14 days combined 
time. 
 1 
2 
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Figure legends 1 
Figure 1 2 
Schematic illustration outlining the reconstruction of corneal epithelial tissue from human 3 
iPS cells via SEAM formation 4 
PART I: Induction of a SEAM containing various ocular cell anlages (Steps 1-34), indicating 5 
human iPS cell maintenance culture, preparation for differentiation culture, and the induction of 6 
multiple ocular cell lineages that form the SEAM. 7 
PART II: Isolation of corneal epithelial stem/progenitor cells from a SEAM and the steps 8 
required to reconstruct corneal epithelial tissue in vitro (Steps 35-59). This includes corneal 9 
epithelial cell differentiation and isolation, and the generation of corneal epithelial cell sheets 10 
using SEAM-derived corneal epithelial stem/progenitor cells. 11 
 12 
Figure 2 13 
The protocol for SEAM formation and fabrication of corneal epithelial cell sheets. 14 
Human iPS cells should be passaged three to four times in StemFitTM medium on an LN511E8-15 
coated dish. Differentiation culture for inducing SEAM formation should then be initiated by 16 
changing the medium to DM. Corneal epithelial cells can be further induced by changing the 17 
medium to CDM (at four weeks) and then to CEM (at eight weeks); these contain KGF and Y-18 
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27632 for promoting corneal differentiation. After CEM culture at around 12 weeks of 1 
differentiation, the corneal epithelial cells, including stem/progenitor cells, can be isolated by 2 
FACS and cultivated again in CEM and then CMM to develop corneal epithelial tissue. DM: 3 
Differentiation medium, CDM: Corneal differentiation medium, CEM: Corneal epithelial 4 
maintenance medium, CMM: Corneal epithelium maturation medium. 5 
  6 
Figure 3  7 
Characterization of cells in a SEAM 8 
(A) Phase-contrast images for undifferentiated human iPS cell colonies and a SEAM after four 9 
and six weeks of differentiation culture. Scale bars, 200 µm. The macro photo (scale bar, 2 mm) 10 
shows several SEAMs, variously sized. 11 
(B) Characterization of cells in a SEAM by immunostaining for ocular cell-related markers: 12 
PAX6 (PRB-278P, BioLegend, 1:300, green) and p63 (4A4, Santa Cruz Biotechnology, 1:200, 13 
red) indicate corneal epithelial cells at four weeks of differentiation; PAX6 (AD2.35, Santa Cruz 14 
Biotechnology, 1:60, green) and -crystallin (SPA-224, Stressgen Biotechnologies, 1:200, red) 15 
indicate lens cells at four weeks of differentiation); TUBB3 (T2200, Sigma-Aldrich, 1:100, 16 
green) and p63 (4A4, Santa Cruz Biotechnology, 1:200, red) indicate neuronal/epithelial cells at 17 
four weeks of differentiation); p75 (ME20.4, Advanced Targeting Systems, 1:100, green) and 18 
42 
 
SOX10 (N20, Santa Cruz Biotechnology, 1:100, red) indicate neural crest cells at two weeks of 1 
differentiation); MITF (C5, Exalpha Biologicals, 1:2000, green) and CHX10 (N-18, Santa Cruz 2 
Biotechnology, 1:500, red) indicate retinal cells at seven weeks of differentiation using the 3 
protocol for retinal differentiation. CRYA: -crystallin, Nuclei, Blue. Scale bars, 100 µm. 4 
 5 
Figure 4 6 
Isolation of corneal epithelial cells from a SEAM 7 
(A) Enrichment of corneal epithelial-type cells from zone 3 of the SEAM by manual pipetting at 8 
seven weeks of differentiation. Scale bars, 200 µm. 9 
(B) A 12-week differentiated SEAM-derived cells that underwent pipetting. Scale bars, 200 µm. 10 
(C) Isolation of corneal epithelial cells by FACS using anti-TRA-1-60, SSEA-4 and ITGB4 11 
antibodies from 14-week differentiated human iPS cells (upper graphs). In the TRA-1-60 12 
negative cell population, 12% of the cells are corneal epithelial cells defined as SSEA-13 
4+/ITGB4+ cells (range typically 5-20%). The results for the cells stained with isotype control 14 
antibodies are shown in lower graphs indicating almost no cells (<0.1%) in the SSEA-15 
4+/ITGB4+ region. 16 
 17 
Figure 5 18 
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Fabrication of a corneal epithelial cell sheet 1 
Immunostaining of human SEAM-derived cell sheets (upper panels; 23 days: lower panels; 76 2 
days of cultivation on cell culture inserts after FACS) for corneal epithelial-related markers, 3 
PAX6 (PRB-278P, BioLegend, 1:300), p63 (4A4, Santa Cruz Biotechnology, 1:200), K12 (N16, 4 
Santa Cruz Biotechnology, 1:200), K3 (AE5, PROGEN Biotechnik, 1:200), MUC1 (M4H2, 5 
Abcam, 1:200) and MUC16 (OV185:1, Abcam, 1:200). Nuclei stain red. Scale bars, 50 µm. 6 
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